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pAre There Progressive Brain Changes in
Schizophrenia? AMeta-Analysis of Structural Magnetic
Resonance Imaging Studies
Bayanne Olabi, Ian Ellison-Wright, Andrew M. McIntosh, Stephen J. Wood, Ed Bullmore, and
Stephen M. Lawrie
Background: It is well established that schizophrenia is associated with structural brain abnormalities, but whether these are static or
progress over time remains controversial.
Methods: A systematic review of longitudinal volumetric studies using region-of-interest structural magnetic resonance imaging in
patientswith schizophrenia and healthy control subjects. The percentage change in volumebetween scans for each brain region of interest
was obtained, and data were combined using random effects meta-analysis.
Results: Twenty-seven studies were included in the meta-analysis, with 928 patients and 867 control subjects, and 32 different brain
regions of interest. Subjects with schizophrenia showed significantly greater decreases over time in whole brain volume, whole brain gray
matter, frontal gray and white matter, parietal white matter, and temporal white matter volume, as well as larger increases in lateral
ventricular volume, than healthy control subjects. The time between baseline and follow-up magnetic resonance imaging scans ranged
from 1 to 10 years. The differences between patients and control subjects in annualized percentage volume change were.07% for whole
brain volume,.59% forwholebraingraymatter,.32% for frontalwhitematter,.32% forparietalwhitematter,.39% for temporalwhite
matter, and.36% for bilateral lateral ventricles.
Conclusions: These findings suggest that schizophrenia is associated with progressive structural brain abnormalities, affecting both gray
and white matter. We found no evidence to suggest progressive medial temporal lobe involvement but did find evidence that this may be
partly explainedbyheterogeneitybetween studies inpatient ageand illnessduration. The causes andclinical correlates of theseprogressive
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T he issue of whether schizophrenia is a progressive brain dis-order has been unresolved since the time of Emil Kraepelin(1). He described an early-onset dementia with progressive
ental deterioration because of degeneration of the frontal and
emporal neocortices. More than 100 years later, disease progres-
ion in schizophrenia remains a disputed topic among researchers
2–4). Some early longitudinal pneumoencephalography and com-
uted tomography studies reported progressive increases in ven-
ricular size in patients over time (5–7) but the majority did not
8–15). These studies tended, however, to have no control subjects
or comparison, could only makemeasurements with considerable
rror, and did not have sufficient power to detect relatively subtle
hanges over time.
Whether or not there are progressive structural brain changes in
chizophrenia is of fundamental importance as to whether schizo-
hrenia is a neurodevelopmental or neurodegenerative disorder
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doi:10.1016/j.biopsych.2011.01.03216). The neurodevelopmental model posits that disturbances
ausedby susceptibility genes and environmental insults occurring
uring early life cause developmental brain insults that culminate
n the onset of schizophrenia decades later (17–20). This is sup-
orted by observations that obstetric complications are associated
ith schizophrenia in later life (21,22), that aberrant early postnatal
rain maturation and synaptogenesis are possible in those who
ater develop schizophrenia (23,24), that there is an absence of
liosis at postmortem (25), and that several brainmorphology stud-
es have demonstrated structural brain volume differences even
efore the emergence of psychotic symptoms (26–28). The dichot-
my of the neurodevelopmental and neurodegenerative hypothe-
es is, however, somewhat artificial, as the pathophysiology of
chizophrenia may encompass both processes.
The hypothesis that schizophrenia has a progressive and even
eurodegenerative component has re-emerged in recent years,
ased primarily on some prospective longitudinal magnetic reso-
ance imaging (MRI) studies (29–33). Studies addressing the issue
f progressive brain structural changes during the course of the
chizophrenia have, however, yielded mixed results (2–4). An
vailable technique to resolve such discrepancies is to conduct a sys-
ematic review and meta-analysis of the literature. Several meta-
nalyses have demonstrated replicable abnormalities in cross-sec-
ional MRI studies of patients with first-episode and chronic
chizophrenia. Reductions in whole brain and gray matter volume,
rimarily in the prefrontal and temporal lobes, and enlargement of
he lateral ventricles compared with healthy control subjects are
mong the most replicated findings (34–37), which are largely evi-
ent at first episode (38,39). Two anatomic likelihood estimation
eta-analyses of cross-sectional, voxel-based morphometry MRI
tudies have identified structural morphometric differences be-
ween studies of patients with first-episode schizophrenia and
BIOL PSYCHIATRY 2011;70:88–96


















































B. Olabi et al. BIOL PSYCHIATRY 2011;70:88–96 89those of chronic schizophrenia, suggesting progressive brain
changes during the course of the illness (40,41), although such
comparisons between two sets of cross-sectional design case-con-
trol studies are unable to exclude the possibility that apparent
differences related to chronicity of illness simply reflect the selec-
tion of more severely ill patients in samples of chronic schizophre-
nia. A meta-analysis of longitudinal studies is therefore required to
clarify the course of putative progressive structural abnormalities in
schizophrenia. The need for this evidence was highlighted at a
meeting attended by researchers worldwide held by the American
College of Neuropsychopharmacology (42). The aim of this system-
atic review and meta-analysis was to quantitatively characterize
any morphometric differences over time in patients with schizo-
phrenia compared with healthy control subjects by 1) identifying
prospective longitudinal MRI studies measuring tissue volume in
regions of interest (ROIs), and 2) synthesizing findings from these
eligible primary studies using random-effects meta-analysis.
Methods andMaterials
Literature Search
A comprehensive search of the electronic databases EMBASE
(from 1980), PsycINFO (from 1801), and Ovid MEDLINE (from 1950)
was conductedusing the following search strategy: ([Magnetic Res-
onance Imaging]OR [MRI]) AND ([Schizophrenia] OR [schizo*]) AND
([Cohort] OR [Prospective] OR [Longitudinal] OR [Follow-up] OR
[Follow adj2 up] OR [Repeat] OR [Reassessed] OR [Change adj2
time]). Both free-text and expandedmedical subject headingswere
used. The search strategy was supplemented using a cited refer-
ence search and by inspecting the reference lists and citing articles
of included papers. The initial search was conducted in May 2009
and was then updated to the end of September 2009.
Criteria for Inclusion/Exclusion
Studies were considered for the review using the following in-
clusion criteria: 1) they were published in English as a peer-re-
viewed article (rather than a letter, abstract, or case report); 2) they
compared a sample of formally diagnosed subjects with a group of
unrelated healthy control subjects; 3) cases and control subjects
were followed-up over a specified time period, with two or more
MRI scans taken; 4) they used ROI volumetric analysis of structural
MRI data; and 5) the means and standard deviations of the volume
change over time of the brain region under studywere reported (or
couldbeextractedor retrieved from the authors) for both cases and
healthy control subjects. Studies of both child-onset schizophrenia
(COS) and adult-onset schizophrenia (AOS) were included.
Studies were excluded if 1) there were insufficient data to ex-
tract thenumberof subjects in eachgroup; 2) therewere fewer than
five subjects in either the schizophrenia group or the comparison
group; 3) the comparison groups consisted of patients with minor
nonpsychiatric illnesses; 4) the structuremeasurement was an area
(from a single slice) rather than a volume (i.e., frommultiple slices);
5) the studies used the voxel-based morphometry, deformation-
based morphometry, or tensor-based volumetric method for mea-
suring brain regional volumes; and 6) the data contributed to an-
other publication, in which case the publication with the largest
group size for each specific brain region under study was selected.
Data Abstraction
Clinical heterogeneity, sample characteristics, and anatomical
landmarks for ROI are likely to be themain factors leading to heter-
ogeneous results. Therefore, data extracted from the studies in-
cluded the authors, year of publication, demographic variables
(number of subjects, age at baseline, gender, and handedness), Dllness variables (diagnosis and duration of illness), duration of fol-
ow-up, and the mean and standard deviation of the percentage
hange in volume of each of the brain regions under study. The
ercentage volume change over time in each study was calculated
sing the following formula:
(Volume at follow-up- Volume at baseline)
Volume at baseline
× 100
We also calculated the sex andhandedness distributions and the
otal numbers of subjects according to the original studies.
tatistical Analysis
Cohen’s estimator of standardized effect size and its variance
as calculated from each study using pooled means and standard
eviations. When articles provided data for defined subgroups (for
xample, by sex or illness stage), data were combined such that
ach study contributedonly onedata point per regionof interest to
he meta-analysis.
Standardized effect sizes were combined to produce a single
ummary estimate using random-effects techniques based on the
ethod ofmaximum likelihood (43). We also estimated annualized
ates of tissue loss in patients and control subjects by dividing the
ercentage volume change over time in each study by the mean
nterscan interval. We used these as the rawmeans for meta-analy-
is and combined them by the Cooper-Hedges method (44).
Publication biaswas assessed using Egger’s test. Themagnitude
fbetween-studyheterogeneitywas estimatedusing the I2 statistic
a measure of the proportion of variance in summary effect size
ecause of heterogeneity) and its statistical significance calculated
sing Cohen’s q (45). Significant heterogeneity was then explored
sing weighted linear regression, with the study effect size as the
ndependent variable and either age, interscan interval, or illness
uration before baseline separately as the dependent variable.
Statistical analysis was performed using R (R Foundation for Sta-
istical Computing, Vienna, Austria; http://www.R-project.org). The
etapackagewasused toperformall statistical summaries except for
he meta-regression analyses, which were performed using the lme
ackage.
esults
The electronic literature search of the three databases yielded
86 articles, of which 151 were retrieved in full-text format (Figure
1 in Supplement 1). Fifty-three studies were identified as being
otentially appropriate to be included in the meta-analysis. How-
ver, seven of these studies concerned regions thatwere not exam-
ned in any other paper and so were not suitable for meta-analysis.
everal studies did not report means and standard deviations of
rain volume changes over time, in which case we contacted the
tudy authors and requested additional data. Most authors com-
lied with our requests but data from six studies were unavailable
pon request. A further 13 studies were excluded on the basis of
ublishing data on overlapping patient groups, in which case we
ook the most recent and largest data set.
Twenty-seven patient cohorts from 25 different articles were
dentified as suitable to be included in the meta-analysis, having
ublished both baseline and follow-up ROI volumetric measures
sing structural MRI techniques and containing sufficient data, in-
luding means and standard deviations of percentage volume
hanges of defined brain regions in schizophrenia patients and
ealthy control subjects. We also contacted the corresponding au-
hors of articles for complementary information where necessary.
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wbrain volumeand lateral ventricular volumechanges reportedmost
often. Table 1 summarizes the information about demographic and
clinical variables of the subjects and control subjects in the 27
independent patient cohorts we identified.
A total of 1795 subjects in the 27 studies were included, which
comprised 928 patients and 867 control subjects. Among the pa-
tient group, the smallest size samplewas 13 schizophrenia patients
(53), and the largest size samplewas 96 schizophrenia patients (32).
hese studies were published from 1997 to 2009.
emographic Characteristics
The mean age of patients with schizophrenia in the included
tudies ranged from 13.9 to 42.7 years. Altogether seven studies
48,50,51,54,55,59,66) comprised samples of people with child-
ood- or adolescent-onset schizophrenia. The youngest patient
ample was from a study of childhood-onset schizophrenia (mean
ge 13.9 years, SD 2.3) (48). The remaining 19 studies were all
dult patient samples ranging fromameanof 22.7 years (33) to 42.7
ears (64,65). The percentage ofmale patients in each study ranged
rom 40% to 100% (48,58,67), with male patients greatly outnum-
ering female patients overall (male patients n  668, female pa-
ients n 260).
eta-Analysis
Random effects analyses were conducted for the 32 ROI and
esults presented in Figure 1 and Table 2.
Whole Brain and Lateral Ventricles. Greater global brain vol-
Table 1. Demographic Characteristics of Included Study Populations













eLisi (1997) (29) 50 65 — 27.4 1.2
air (1997) (46) 18 78 — 30.9 8.6
Gur (1998) (47) 40 58 — 29.2 5.7
Rapoport (1999) (48) 15 40 73 13.9 3.6
aijo (2001) (30) 18 50 — 37.5 15.1
ood (2001) (49) 42 71 — 25.2 3.1
ahn (2002) (31) 34 85 91 26.2 1.4
ames (2002, 2004) (50,51) 9 100 100 17.7 2.0
7 0 80 15.3 1.0
Ho (2003) (52) 73 73 — 24.5 3.0
Kasai (2003) (53) 13 77 79 27.2 .4
Keller (2003) (54) 35 57 60 14.5 4.2
Sporn (2003) (55) 39 61 — 15.0 4.6
DeLisi (2004) (56) 26 65 96 27.4 1.2
Molina (2005) (57) 29 69 100 27.8 4.5
Whitworth (2005) (58) 38 100 100 23.7 3.9
ddington (2007) (59) 49 61 67 14.5 5.8
akamura (2007) (60) 17 82 77 24.7 —
rans (2008) (61) 19 53 89 38.6 15.7
ais (2008) (33) 51 88 88 22.7 1.0
an Haren (2008) (32) 96 73 86 32.2 11.0
ang (2008) (62) 56 66 — 36.6 15.7
oolschijn (2009) (63) 68 79 85 34.5 12.6
itelman (2009) (64,65) 49 86 96 42.7 18.7
eig (2009) (66) 16 100 94 15.7 .3
5 0 80 15.7 .3
oshida (2009) (67) 16 100 80 38.6 16.3
Data for age at initial MRI, illness duration, and duration of inter-MRI inte
M, male subjects; MRI, magnetic resonance imaging; n, number of subjeume reductions were found in patients with schizophrenia over r
ww.sobp.org/journalime in subjects compared with healthy control subjects (n  14
tudies; Cohen’s d:.40; 95%confidence interval [CI]:.62 to.19)
Figure 1). This effect was also significant for whole brain gray mat-
er (n 12; d:.52; 95% CI:.76 to.28), although no differences
ere found for whole brain white matter, whole brain cerebrospi-
al fluid, and cerebellar volume.
The analyses also demonstrated greater increases in bilateral
ateral ventricular volume over time in subjects with schizophrenia
ompared with control subjects (n  10; d: .53; 95% CI: .28 to .78)
Figure 1), whereas no significant difference in third ventricular
olume change between groups was detected.
Frontal, Parietal, Temporal, andOccipital Lobes. Therewere
ignificant reductions over time in patients with schizophrenia
ompared with control subjects in frontal lobe volume (n  3; d:
.48; 95%CI:.78 to.18), frontal lobe graymatter (n 9; d:.34;
5%CI:.66 to.02), frontal lobewhitematter (n 5; d:.51; 95%
I:.76 to.26), parietal lobewhitematter (n 4; d:.53; 95% CI:
.84 to.23), and temporal lobewhitematter (n 6; d:.49; 95%
I:.76 to.21).
No significant differences were found between groups for fron-
al lobe cerebrospinal fluid, parietal lobe gray matter, parietal lobe
erebrospinal fluid, temporal lobe tissue, right and left temporal
obes, temporal lobe gray matter, temporal lobe cerebrospinal
uid, or occipital lobe gray and white matter.
Hippocampi, Amygdalae, and Caudate Nuclei. No signifi-














4.7 20 60 — 26.5 4.3
2.6 5 40 — 40.6 2.6
2.5 17 76 — 31.9 2.7
4.2 34 50 88 12.8 4.3
10.0 12 58 — 37.1 10.0
2.0 26 54 — 23.8 2.2
1.1 36 83 86 24.5 1.0
2.4 9 100 69 15.7 1.7
3.1 7 0 60 16.4 1.7
3.3 23 65 — 26.9 3.4
1.4 14 93 79 25.6 1.6
2.4 34 59 82 14.5 2.8
2.4 43 63 — 14.8 2.7
10.0 10 60 90 26.5 10.0
2.2 11 55 100 28.4 2.3
2.9 20 100 100 27.8 3.7
2.4 107 62 93 14.5 2.8
1.5 26 85 75 23.6 1.5
5.0 54 63 76 35.5 4.8
5.3 31 81 84 24.7 5.2
4.8 113 67 85 35.3 4.9
2.2 62 55 — 36.2 2.2
4.8 83 66 87 38.0 4.9
4.1 16 56 100 41.6 4.2
2.0 21 100 86 15.2 2.0
2.0 13 0 85 15.2 2.0
3.1 20 100 80 40.9 1.4
re expressed as means.
H, right-handed patients; —, no data available.s
on
s)


























































B. Olabi et al. BIOL PSYCHIATRY 2011;70:88–96 91gressive decreases in left caudate volume were found in subjects
with schizophrenia comparedwith control subjects (n 3; d:.34;
5% CI:.60 to.07).
Annual Percentage Changes. Using the Cooper-Hedges
method, the annual percentage volume change difference be-
tween patients and control subjects were derived (Table S1 in Sup-
plement 1). Where statistically significant differences emerged be-
tweenpatients and control subjects in terms of progression overall,
the difference between patients and control subjects in annualized
percentage volume change were .07% for whole brain volume,
.59% for whole brain gray matter, .32% for frontal lobe white
matter, .32% for parietal lobe white matter,.39% for temporal
lobe white matter, and 36% for bilateral lateral ventricles.
Publication Bias, Heterogeneity Bias, andMeta-Regression
Analyses
Egger’s test and subsequent multiple comparisons correction
analysis indicated that there was no significant relationship be-
tween studyprecision andestimatedeffect size for anybrain region
of interest considered by this meta-analysis, indicating no signifi-
cant evidence of publication bias.
Statistically significant clinical heterogeneity was detected in
several brain regions (wholebrain volume,wholebraingraymatter,
whole brain white matter, bilateral lateral ventricles, left lateral
ventricle, frontal gray matter, frontal cerebrospinal fluid, parietal
gray matter, parietal cerebrospinal fluid, temporal gray matter, oc-
Figure 1. Forest plots (random effects) showing the mean difference in
percentage change over time in (A) whole brain volume and (B) lateral
entricles in schizophrenia subjects andhealthy control subjects. SMD, stan-
ard mean difference.cipital gray matter, and right hippocampus). Regions in which no ceterogeneitywas foundand that showed significantdifferences in
olume change over time include the frontal lobe tissue, frontal
hite matter, parietal white matter, and temporal white matter.
The modifying effects of age, illness duration, and interscan
nterval were investigated using meta-regression, to examine
actors that could contribute to heterogeneity between study
esults. Although more than 20 individual tests were conducted,
nly three significant associations between these variables and
ffect size were revealed. Age at study entry was positively associ-
ted with the effect size in the right hippocampus. Because the
verall estimate for this structure was negative, implying a greater
eduction in subjects with schizophrenia, this finding suggests that
he magnitude of this reduction diminishes with increasing age.
urthermore, illness duration before baseline was negatively asso-
iatedwith the effect size in the right and left hippocampi, implying
hat themagnitudeof this reduction increaseswith increasingprior
uration of illness. No modifying effect of interscan interval was
een.
To address possible effects of age at onset, we conducted tests
f potential child- versus adult-onset schizophrenia stratification in
TATA (StataCorp, College Station, Texas) using the metan.ado
cript. There was no overall heterogeneity between these sub-
roups (p .8). There was, however, significant heterogeneity be-
ween the groups for frontal gray matter, indicating possibly
reater tissue loss in COS (standard mean difference  .6, three
tudies) than AOS (standard mean difference  .2, five studies);
ccipital graymatter, COS.5 versus AOS .0 (two vs. three studies);
nd parietal cerebrospinal fluid,.8 versus .3 (one study each) but
o heterogeneity for the hippocampi. It should be noted that only
rontal gray matter was significantly reduced in the full meta-anal-
sis of both groups combined and that only a small number of
tudies have been conducted.
iscussion
rogressive Brain Changes in Schizophrenia
Findings from this systematic review andmeta-analysis suggest
hat patients with schizophrenia in comparison with healthy con-
rol subjects exhibit statistically significant progressive reductions
n whole brain, whole brain gray matter, and frontal lobe volumes,
s well as frontal, parietal, and temporal lobe white matter decre-
ents and lateral ventricular volume enlargement over time. In
ontrast, no progressive volumetric changes were detected in
edial temporal lobe subregions, namely the bilateral hip-
ocampi, amygdala, and amygdala-hippocampal complexes.
ur findings are supported by an absence of publication bias.
lthough heterogeneity was considerable and largely unex-
lained, several results were not subject to heterogeneity, and
e used a random effects statistical model to take account of
eterogeneity where evident.
Our results support the idea that schizophrenia has a progres-
ive component to its pathophysiology, although this is not neces-
arily degenerative, and this model and the neurodevelopmental
odel are not mutually exclusive (68). Many of the genes impli-
ated in the illness appear to have functional roles throughout the
ife course, and therefore, it has been suggested that its pathophys-
ology involves an ongoing interplay of genetic, epistatic, and envi-
onmental factors in both early and later life (19,69,70).
The findings of global brain volume reduction and lateral ven-
ricular volumeenlargement over time are consistentwithprevious
ostmortem studies, which have repeatedly documented reduc-
ions in regional cell size (71) and raised the possibility of increased
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wcellular causes of any progressive anatomic MRI changes in schizo-
phrenia is sparse, although there is a general agreement that the
absence of gliosis indicates that widespread cell death is not the
underlying cause. Whether more subtle forms of programmed cell
death (apoptosis), loss of neuropil, or neurochemical perturbations
are important requires further postmortem investigation. Neuro-
psychological investigation in a large patient sample above 65
years of age has demonstrated a further reduction of neurocogni-
tive abilities beyond what would be expected from aging (74),
although most longitudinal studies of neurocognitive function in
schizophrenia have not documented similar changes over time
(75–79). Clearly, more longitudinal imaging studies in schizophre-
nia are required, but these should concentrate on trying to identify
clinical and pathological correlates. The regional effect sizes and
annualized rates of loss we provide should inform power calcula-
tions for these studies.
Regional white matter changes in schizophrenia have been
identified in previous cross-sectional studies (80,81), and it has
been suggested that ventricular enlargement is related to a reduc-
Table 2. Mean Differences in the Percentage Change over Time Across 32 B











hole Brain 14 538 454 .404 .0
erebellum 6 254 222 .029 .7
hole Brain GM 12 405 523 .52 .0
hole Brain WM 11 366 480 .129 .3
hole Brain CSF 6 95 72 .126 .4
ilateral Lateral
Ventricles 10 360 354 .530 .0
ateral Ventricle (R) 5 95 58 .393 .0
ateral Ventricle (L) 5 95 58 .242 .4
hird Ventricle 6 216 250 .180 .0
rontal Lobe Tissue 3 132 94 .478 .0
rontal GM 9 262 241 .340 .0
rontal WM 5 185 138 .512 .0
rontal CSF 3 94 57 .522 .1
arietal GM 7 172 192 .161 .3
arietal WM 4 112 115 .533 .0
arietal CSF 3 94 57 .255 .6
emporal Lobe
Tissue 5 148 110 .089 .6
emporal Lobe (R) 4 108 62 .066 .7
emporal Lobe (L) 4 108 62 .056 .7
emporal GM 10 205 234 .204 .2
emporal WM 6 128 131 .485 .0
emporal CSF 5 110 73 .150 .3
ccipital GM 6 133 149 .174 .4
ccipital WM 4 112 115 .327 .1
AC (R) 5 83 70 .060 .7
AC (L) 5 83 70 .107 .5
ippocampus (R) 8 283 241 .145 .3
ippocampus (L) 8 283 241 .089 .4
mygdala (R) 5 123 112 .138 .3
mygdala (L) 5 123 112 .019 .8
audate (R) 3 155 98 .132 .4
audate (L) 3 155 98 .336 .0
CI, confidence interval; CSF, cerebrospinal fluid; GM, gray matter; HAC
tandard mean difference; WM, white matter.tion in white matter adjacent to the ventricles (82). At a functional c
ww.sobp.org/journalevel, this has been explained in the context of the dysconnectivity
ypothesis (83) because of abnormal synapse formation and plas-
icity (84).Whetherwhitematter changesover timeoccuruniformly
hroughout the brain, perhaps as a result of genetic abnormalities
n the protein pathways controlling myelination, or whether spe-
ific white matter tracts are affected (85) is unclear. A recent meta-
nalysis of cross-sectional diffusion-tensormagnetic resonance im-
ging studies in schizophrenia (86) identified changes in deep
rontal and temporal white matter areas and suggested that the
hite matter changes in schizophrenia were regional rather than
niform. Neuropathological studies of schizophrenia have also de-
ected regional abnormalities in white matter, including axonal
trophy and swelling of periaxonal oligodendrocyte processes es-
ecially in the frontal lobe (87). In this meta-analysis, we identified
ignificant reductions in frontal, temporal, and parietal, but not
lobal, white matter, suggesting that multifocal regional reduc-
ions may continue to occur over time. We note, however, that the
5% confidence intervals of these global and local estimates show
arge overlap and are therefore in keeping with each other statisti-







(.62, .19) 57.0 30.2 .004 (47,48,49, 31,50,51,52,54,55,57,60,
33,32,64,65)
(.17, .22) 5.2 5.3 .383 (31,50,51,52,54,32)
(.76, .28) 62.3 29.2 .002 (48,31,54,55,57,59,60,33,32,66)
(.41, .15) 70.6 34.0 .0002 (48,31,54,57,59,60,33,32,66)
(.24, .49) 14.1 5.8 .324 (46,47,50,51,66)
(.28, .78) 51.7 18.6 .029 (30,31,50,51,52,55,60,33,32)
(.03, .76) 10.6 4.5 .346 (30,50,51,56,58)
(.33, .82) 62.1 10.6 .032 (30,50,51,56,58)
(.01, .37) .0 5.0 .416 (31,50,51,60,33,32)
(.78, .18) .0 .2 .922 (47,52,60)
(.66, .02) 59.8 19.9 .011 (48,52,55,57,60,64,65,66)
(.76, .26) .0 1.2 .886 (48,52,57,60,64,65)
(.16, 1.21) 64.8 5.7 .058 (66)
(.50, .18) 52.6 12.7 .049 (48,55,57,60,64,65,66)
(.84, .23) 4.0 3.1 .373 (48,57,60,64,65)
(1.24, .73) 82.5 11.5 .003 (52,66)
(.49, .31) 47.5 7.6 .107 (47,50,51,52,60)
(.45, .31) 22.1 3.9 .278 (28,49,50,51)
(.26, .37) .0 .3 .964 (28,49,50,51)
(.58, .17) 68.0 28.1 .001 (48,50,51,55,57,60,64,65,66)
(.76, .21) .0 3.9 .569 (48,50,51,57,60,64,65)
(.17, .47) .0 2.0 .732 (50,51,52,66)
(.67, .32) 69.9 16.6 .005 (48,57,60,64,65)
(.74, .08) 45.9 5.5 .136 (48,57,60,64,65)
(.38, .26) .0 1.5 .836 (50,51,53,58,67)
(.22, .43) .0 .6 .969 (50,51,53,58,67)
(.15, .44) 57.2 16.4 .022 (28,49,50,51,53,58,62,63)
(.16, .34) 42.9 12.3 .093 (28,49,50,51,53,58,62,63)
(.43, .16) 12.5 4.6 .334 (50,51,53,58,62)
(.24, .28) .0 1.1 .888 (50,51,53,58,62)
(.49, .23) 41.6 3.4 .180 (28,62,64,65)
(.60, .07) .0 .9 .641 (28,62,64,65)
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While it has been suggested that both neurodevelopmental
deviance and progressive degenerative change could be possible
(4,88,89), Weinberger and McClure (2) proposed that the findings
being presented in longitudinal MRI studies were artifactual. A po-
tential confounding factor of all neuroimaging studies in schizo-
phrenia is the effect of antipsychotic medication, but establishing
whether structural brain changes over time are a result of medica-
tion or the illness itself is challenging (3). Neuroimaging studies
during the early phase of the illness are useful, because the con-
founding effects of chronicity and long-term medication can be
minimized (90–92). In a recent systematic review, Moncrieff and
Leo (93) investigated the possible role of antipsychotics in the gen-
esis of brain volume abnormalities in schizophrenia, documenting
thatmost longitudinal studies report graymatter volumedecreases
or ventricular volume increases during the course of drug treat-
ment. Observations of coincident volume change and antipsy-
chotic medication prescription do not, however, prove that loss of
brain tissue is a direct consequence of the drug, even if the timing
may suggest this. Until evidence from randomized controlled trials
and neuromolecular studies investigating the pathophysiological
basis of these findings emerge, we cannot be certain whether or to
what extent the anatomical changes can be attributed to antipsy-
chotic medication. Indeed, the fact that similar changes have been
reported inunmedicated individuals as theydevelop schizophrenia
argues against medication being entirely responsible (94). In our
meta-analysis, among the 27 studies reviewed, none of the studies
included purely antipsychotic-naive schizophrenia patients, and
such a study is desirable, even though it would be difficult and
arguably unethical to conduct. Illness duration before initial MRI
ranged from less than 1 year (53,66) to 18.7 years (64,65), but this
was only apparently associated with heterogeneity concerning
progression in the hippocampus. Furthermore, increasing age (and
presumably increasingmedication exposure)was associatedwith a
reducing effect size.
Our stratification analyses comparing adult- and childhood-on-
set schizophrenia suggest that there may be differential effects in
these subgroups. Given that only frontal gray matter was signifi-
cantly reduced in the full meta-analysis of both groups combined
and the small number of studies involved, these possibly differen-
tial effects by age at onset require very cautious interpretation and
further study. Indeed, it should be noted that all the longitudinal
studies in this review may suffer from cohort effects, given that
older patients lived in a different time than youngpatients andmay
have experienced different approaches to their care. Even studies
that included subjects across a large age range with a relatively
short scan interval still suffer from such potential cohort effects.
Another possible explanation for heterogeneity between stud-
ies is gender. Female patients with schizophrenia are underrepre-
sented in the literature, despite interest in the effects of gender in
the pathophysiology of schizophrenia (95) and healthy aging pop-
ulations (96). Although findings have not been consistent, several
investigators have reported sex differences in brain morphology in
schizophrenia (97,98). The absolute number of male subjects in-
cluded in thismeta-analysiswasover two timesgreater than female
subjects, and although two groups reported percentage change in
volume over time data for female subjects andmale subjects sepa-
rately (50,51,66), the effects of gender could not be fully explored
without individual patient data. Left-handed subjects are also un-
derrepresented in the analysis, again, possibly contributing to in-
creased heterogeneity of study results.
An important methodological consideration in follow-up MRI
studies is the effect of technical scanner software upgrade and thanges in signal-to-noise ratio (99) on the reproducibility of brain
olume data. Ideally, a longitudinal study should utilize high-reso-
ution imaging techniques, thin slices, and no gaps between slices
or more precise magnetic resonance morphometric volume mea-
ures (100). Methodological differences between research groups
re a potential limitation in meta-analyses such as that reported
ere.
trengths and Limitations of the Review
Despite several years of accumulated data on progressive struc-
ural brain change in people with schizophrenia and although sev-
ral narrative reviews on this topic have been published
3,4,88,101–110), this review is the first to systematically and quan-
itatively meta-analyze progressive change data from schizo-
hrenic and control subjects, including 32different brain regions of
nterest. Narrative reviews tend to be limited by focusing on pub-
ished studies and especially those that report statistically signifi-
ant results. In thismeta-analysis, each study isweighted according
o the sample size, thus reducing the possibility of biased interpre-
ation of the findings. While the selective publication of positive
ata is a potential limitation of this and all other meta-analyses, we
ound no evidence of publication bias. Our results are in keeping
ith andextend thefindings of a previousmeta-analysis that found
vidence of progressive increases in the lateral ventricles but did
ot examine other regions of interest (111). Since our literature
earch, both positive (112) and negative (113) studies have been
ublished. These studies are consistent with the results reported
ere and attest to the need for a comprehensive, quantitative re-
iew of the literature as awhole. The annualized rates of changewe
eport should help to plan future studies.
Meta-analysis of region-of-interest studies, restricted to brain
obes and defined anatomical regions, constrains findings to large-
cale changes in the brain. Analysis of voxel-based morphometry
tudies would complement this study, allowing the analysis of
mall-scale regional gray and white matter volume abnormalities
ot necessarily related tomajor subdivision in brain regions. It may
ell be the case that reductions of the magnitude identified here
re very difficult to detect in small brain regions of interest such as
he hippocampus and amygdala (4,107).
onclusions
We reviewed 27 studies that used regional brain volume mea-
urements to identify progressive changes in brain volume over
ime in patients with schizophrenia and control subjects. Meta-
nalyses revealed that schizophrenia is associated with significant
eclines in whole brain volume, whole brain gray matter, and fron-
al lobe volume over time, as well as increases in lateral ventricular
olume compared with healthy control subjects. There was no evi-
ence of progressive medial temporal lobe involvement in schizo-
hrenia. The causes and clinical correlates of these changes should
ow be the focus of investigations.
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